Erickson Michael G 4

What Happened
Michael G. Erickson, Executive Vice President of IDEXX Laboratories (IDXX), executed multiple option exercises (transaction code M) and related open‑market sales (S) between Feb 17 and Feb 19, 2026. He exercised a total of 7,770 option shares (various exercise prices) for approximately $1.46M in aggregate exercise cost, and sold 5,371 shares in market transactions on Feb 17 for total proceeds of about $3.37M. Net effect in this filing: +2,399 shares acquired and retained (7,770 exercised minus 5,371 sold).

Key Details

• Transaction dates: Feb 17, 2026 (majority of activity) and Feb 19, 2026. Filing date: Feb 19, 2026 (within Form 4 timing requirements).
• Exercises (M): 7,770 shares exercised at various prices (examples: 1,191 @ $141.60; 4,180 @ $178.26; 483 @ $206.94; smaller tranches at $505–$544). Aggregate exercise cash outlay ≈ $1,460,329.
• Sales (S): 5,371 shares sold in several tranches on Feb 17 at weighted average prices in the low-to-high $623–$629 range (proceeds ≈ $3,369,666). Footnotes F1–F5 provide the specific weighted price ranges per tranche.
• Shares owned after transaction: not specified in the excerpt of the filing provided here.
• Notable footnotes: F10–F13 indicate the exercised options were from grants that vested (single-installment vesting on Feb 14 of 2023–2026 and earlier grants F7–F9); F6 notes 184 vested but deferred restricted stock units are included in holdings.
• Timeliness: filing was made Feb 19 for transactions through Feb 17; no late-file indication in this report.

Context

• What "M" and "S" mean: M = exercise/conversion of derivative security (options); S = open‑market sale. The filing shows exercises and matching sales on Feb 17 for the same number of shares (exercise entries paired with zero‑dollar derivative disposals and separate market sale entries), which is consistent with immediate sale of exercised shares. The Feb 19 exercises are reported without corresponding open‑market sale entries in this filing, indicating those shares were not sold in the same report.
• For retail investors: purchases (exercises where shares are retained) can be interpreted as a form of insider buying, while sales are often routine (e.g., to cover exercise cost or taxes). This Form 4 is factual record of the exercises and sales; it does not state the insider’s motives.